Advertisement
CHRS vs DERM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and DERM is a Hold.
| CHRS | DERM | CHRS / DERM | |
| Capitalization | 209M | 208M | 100% |
| EBITDA | -148.46M | 1.89M | -7,838% |
| Gain YTD | -4.930 | -5.188 | 95% |
| P/E Ratio | 3.24 | 39.08 | 8% |
| Revenue | 50.9M | 68.2M | 75% |
| Total Cash | 105M | 25.6M | 410% |
| Total Debt | 39.7M | 25.5M | 156% |
CHRS | DERM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 96 | |
PRICE GROWTH RATING 1..100 | 73 | 42 | |
P/E GROWTH RATING 1..100 | 70 | 34 | |
SEASONALITY SCORE 1..100 | n/a | 37 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CHRS's Valuation (54) in the Biotechnology industry is in the same range as DERM (60). This means that CHRS’s stock grew similarly to DERM’s over the last 12 months.
CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DERM (100). This means that CHRS’s stock grew similarly to DERM’s over the last 12 months.
DERM's SMR Rating (96) in the Biotechnology industry is in the same range as CHRS (99). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.
DERM's Price Growth Rating (42) in the Biotechnology industry is in the same range as CHRS (73). This means that DERM’s stock grew similarly to CHRS’s over the last 12 months.
DERM's P/E Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for CHRS (70). This means that DERM’s stock grew somewhat faster than CHRS’s over the last 12 months.
| CHRS | DERM | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 70% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 83% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 88% |
| Advances ODDS (%) | 1 day ago 77% | 6 days ago 87% |
| Declines ODDS (%) | 4 days ago 90% | 4 days ago 84% |
| BollingerBands ODDS (%) | 1 day ago 72% | 1 day ago 90% |
| Aroon ODDS (%) | 3 days ago 84% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CHRS’s FA Score shows that 0 FA rating(s) are green while DERM’s FA Score has 0 green FA rating(s).
- CHRS’s FA Score: 0 green, 5 red.
- DERM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CHRS’s TA Score shows that 4 TA indicator(s) are bullish while DERM’s TA Score has 7 bullish TA indicator(s).
- CHRS’s TA Score: 4 bullish, 5 bearish.
- DERM’s TA Score: 7 bullish, 4 bearish.
Price Growth
CHRS (@Biotechnology) experienced а +1.50% price change this week, while DERM (@Pharmaceuticals: Generic) price change was +1.11% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.53%. For the same industry, the average monthly price growth was -8.46%, and the average quarterly price growth was +7.13%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.59%. For the same industry, the average monthly price growth was -5.72%, and the average quarterly price growth was +39.19%.
Reported Earning Dates
CHRS is expected to report earnings on Nov 09, 2026.
DERM is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (+1.53% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+2.59% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement